Clinical Research Directory
Browse clinical research sites, groups, and studies.
AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)
Sponsor: Erasme University Hospital
Summary
While most of the children spontaneously recover menstruation or experienced normal puberty after chemotherapy, their ovarian reserve may be impaired by treatment inducing future infertility. Fertility preservation is currently proposed for selected prepubertal patients with a high risk of premature ovarian failure after treatment (mostly conditioning regimen for bone marrow transplantation). For patients with low or moderate risks, counselling is very difficult and no fertility preservation procedure is usually proposed for these patients as no marker of the ovarian reserve has been validated in this young population to assess the individual risk. The primary objective of the study is to prevent long-term treatment-related infertility by detecting the young patients who normally progressed to menarche but have a reduced ovarian reserve. These patients may benefit from particular follow-up and fertility preservation procedure.
Official title: Antimüllerian Hormone as a Predictor of Future Infertility Risk in Prepubertal/Pubertal Cancer Patients
Key Details
Gender
FEMALE
Age Range
3 Years - 14 Years
Study Type
OBSERVATIONAL
Enrollment
275
Start Date
2014-04
Completion Date
2036-12
Last Updated
2020-05-04
Healthy Volunteers
No
Interventions
No intervention
No intervention
Locations (10)
Centre Hospitalier Chrétien (CHC)- Clinique de l'espérance
Montegnée, Liège, Belgium
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium
Hôpital Universitaire Reine Fabiola (HUDERF)
Brussels, Belgium
Universitair Ziekenhuis Brussels
Brussels, Belgium
UZ-Gent
Ghent, Belgium
Universitair Ziekenhuis Leuven
Leuven, Belgium
Centre Hospitalier Régional (CHR)-Citadelle
Liège, Belgium
Centre Oscar Lambret
Lille, France
CHRU Lille-Hôpital Jeanne de Flandre
Lille, France
Hôpital Robert Debré
Paris, France